Appendix B: Drug Characteristics Tables
Appendix B, Table 2. Nucleoside Reverse Transcriptase Inhibitor-Based, Fixed-Dose Combination Tablets for Use as Part of an Antiretroviral Regimen
The following table includes dose recommendations for Food and Drug Administration–approved, dual nucleoside reverse transcriptase inhibitor (NRTI) fixed-dose combination (FDC) products. These FDC tablets are not complete regimens and must be administered in combination with other antiretroviral (ARV) drugs. FDC products that contain zidovudine (ZDV) have been removed from this table. Please refer to the FDA product labels for information regarding ZDV-containing FDCs.
Please see the class-specific drug characteristics tables (Appendix B, Tables 3, 4, 5, and 6) for details about the individual drugs contained in these FDC products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The FDC tablets in this table are listed by trade name.
| Trade Name (Abbreviations) |
ARV Drugs Included in the FDC Tablet | Dosing Recommendationa |
|---|---|---|
| TAF or TDF plus an NRTI | ||
| Descovy (TAF/FTC) |
Tenofovir alafenamide 25 mg/emtricitabine 200 mg | One tablet PO once daily |
| Cimduo (TDF/3TC) |
Tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily |
| Temixys (TDF/3TC) |
Tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily |
| Truvada (TDF/FTC) |
Tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily |
| Other NRTI-Based, FDC Tablets | ||
| Epzicom (ABC/3TC) Note: Generic product is available. |
Abacavir 600 mg/lamivudine 300 mg | One tablet PO once daily |
| a For dose adjustments in patients with renal or hepatic insufficiency, see Appendix B, Table 11. All FDC tablets listed in this table can be taken without regard to food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; FDC = fixed-dose combination; FTC = emtricitabine; NRTI = nucleoside reverse transcriptase inhibitor; PO = orally; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate |
||
Appendix B: Drug Characteristics Tables
Appendix B, Table 2. Nucleoside Reverse Transcriptase Inhibitor-Based, Fixed-Dose Combination Tablets for Use as Part of an Antiretroviral Regimen
The following table includes dose recommendations for Food and Drug Administration–approved, dual nucleoside reverse transcriptase inhibitor (NRTI) fixed-dose combination (FDC) products. These FDC tablets are not complete regimens and must be administered in combination with other antiretroviral (ARV) drugs. FDC products that contain zidovudine (ZDV) have been removed from this table. Please refer to the FDA product labels for information regarding ZDV-containing FDCs.
Please see the class-specific drug characteristics tables (Appendix B, Tables 3, 4, 5, and 6) for details about the individual drugs contained in these FDC products, including information on elimination and metabolic pathways, serum and intracellular half-lives, and adverse effects. The FDC tablets in this table are listed by trade name.
| Trade Name (Abbreviations) |
ARV Drugs Included in the FDC Tablet | Dosing Recommendationa |
|---|---|---|
| TAF or TDF plus an NRTI | ||
| Descovy (TAF/FTC) |
Tenofovir alafenamide 25 mg/emtricitabine 200 mg | One tablet PO once daily |
| Cimduo (TDF/3TC) |
Tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily |
| Temixys (TDF/3TC) |
Tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg | One tablet PO once daily |
| Truvada (TDF/FTC) |
Tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg | One tablet PO once daily |
| Other NRTI-Based, FDC Tablets | ||
| Epzicom (ABC/3TC) Note: Generic product is available. |
Abacavir 600 mg/lamivudine 300 mg | One tablet PO once daily |
| a For dose adjustments in patients with renal or hepatic insufficiency, see Appendix B, Table 11. All FDC tablets listed in this table can be taken without regard to food. Key: 3TC = lamivudine; ABC = abacavir; ARV = antiretroviral; FDC = fixed-dose combination; FTC = emtricitabine; NRTI = nucleoside reverse transcriptase inhibitor; PO = orally; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate |
||
Download Guidelines
- Section OnlyPDF (249.35 KB)
- Full GuidelinePDF (2.44 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)